Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M

TACTILE SYSTEMS TECHNOLOGY INC

2024-Q2 EPS reported $0.09 revenue$134,306,000

Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.
Net income of $4.3M ($0.18 diluted EPS) vs net loss of $0.1M in Q2 2023; adjusted EBITDA $9.1M.
Full-year 2024 revenue guidance lowered to $293-298M (7-9% growth) from prior $300-305M (9-11%).
Appointed Sheri Dodd as President and CEO effective July 1, 2024; received 510(k) clearance for Nimbl system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.